HLS Therapeutics (TSE:HLS) reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company’s newly launched cholesterol drug NILEMDO and continued deleveraging of its balance sheet.
On a conference call discussing results for the three months ended March 31, 2026, Chief Executive Officer Craig Millian said HLS is “in a very favorable position,” citing growth in Vascepa, resilience in Clozaril and what he described as a stronger operational and financial foundation following efficiency improvements and debt reduction.
